We are live on ! Find out more
SL

Siren LLC Portfolio holdings

AUM $3.61B
1-Year Est. Return 203.3%
This Fund
S&P 500
This Quarter Est. Return
+74.07%
1 Year Est. Return
+203.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.26B
AUM Growth
+$263M
Cap. Flow
+$190M
Cap. Flow %
8.39%
Top 10 Hldgs %
48.54%
Holding
134
New
22
Increased
21
Reduced
22
Closed
16

Top Buys

Rank Stock Value
1
SEPN
Septerna Inc
SEPN
+$52.1M
2
BCYC
Bicycle Therapeutics
BCYC
+$39.4M
3
APGE icon
Apogee Therapeutics
APGE
+$38.1M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$35.4M
5
NAMS icon
NewAmsterdam Pharma
NAMS
+$25M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$65.4M
2
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$30.1M
3
WVE icon
Wave Life Sciences
WVE
+$26.3M
4
ARGX icon
argenx
ARGX
+$16.8M
5
BHVN icon
Biohaven
BHVN
+$14.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.88%
2 Technology 3.51%
3 Communication Services 1.85%
4 Consumer Discretionary 0.74%
5 Real Estate 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
26
Revolution Medicines
RVMD
$44B
$25M 1.1%
571,548
-182,053
-24% -$9.19M
PCVX icon
27
Vaxcyte
PCVX
$8.64B
$24.6M 1.08%
299,991
– –
RCUS icon
28
Arcus Biosciences
RCUS
$3.64B
$24M 1.06%
1,612,077
– –
ERAS icon
29
Erasca
ERAS
$6.39B
$22.2M 0.98%
8,857,179
– –
STOK icon
30
Stoke Therapeutics
STOK
$2.11B
$22.1M 0.97%
+2,000,000
New +$24.6M
IGMS
31
DELISTED
IGM Biosciences
IGMS
$20.3M 0.9%
3,330,422
– –
EWTX icon
32
Edgewise Therapeutics
EWTX
$4.73B
$19.6M 0.87%
734,343
+330,230
+82% +$10.5M
SLN
33
Silence Therapeutics
SLN
$564M
$19.5M 0.86%
2,831,770
– –
CYTK icon
34
Cytokinetics
CYTK
$10.4B
$18.9M 0.84%
402,323
-123,648
-24% -$6.42M
DNLI icon
35
Denali Therapeutics
DNLI
$3.97B
$17M 0.75%
834,028
– –
KRRO icon
36
Korro Bio
KRRO
$195M
$15.9M 0.7%
418,833
– –
SLNO
37
DELISTED
Soleno Therapeutics
SLNO
$15.8M 0.7%
+351,818
New +$18.2M
PRTA icon
38
Prothena Corp
PRTA
$450M
$15.2M 0.67%
1,099,840
– –
SLDB icon
39
Solid Biosciences
SLDB
$900M
$15M 0.66%
3,749,041
+1,000,000
+36% +$5.49M
CGEM icon
40
Cullinan Oncology
CGEM
$1.14B
$14.8M 0.65%
1,211,357
– –
UPB
41
Upstream Bio Inc
UPB
$395M
$13.2M 0.58%
+800,000
New +$17.9M
TRVI icon
42
Trevi Therapeutics
TRVI
$2.64B
$12M 0.53%
+2,906,060
New +$9.3M
KURA icon
43
Kura Oncology
KURA
$850M
$11.7M 0.52%
1,339,942
– –
TSHA icon
44
Taysha Gene Therapies
TSHA
$1.89B
$11.4M 0.5%
6,602,475
+1,722,600
+35% +$3.57M
RELY icon
45
Remitly
RELY
$5.14B
$11.1M 0.49%
490,449
+465,449
+1,862% +$8.57M
RNAC icon
46
Cartesian Therapeutics
RNAC
$268M
$10.2M 0.45%
572,236
– –
MSFT icon
47
Microsoft
MSFT
$3.71T
$9.69M 0.43%
23,000
+1,000
+5% +$426K
JANX icon
48
Janux Therapeutics
JANX
$967M
$9.37M 0.41%
+175,000
New +$9.26M
SEER icon
49
Seer Inc
SEER
$120M
$9.24M 0.41%
4,000,000
– –
IONS icon
50
Ionis Pharmaceuticals
IONS
$9.4B
$8.74M 0.39%
250,000
– –
1
2
3 4 5

Similar funds

SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Siren LLC's Q4 2024 Portfolio in Review

As of Q4 2024, Siren LLC held 134 positions worth $2.26B, up 13% from $2B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Siren LLC deployed $190M of net new capital in Q4 2024, opening 22 new positions and adding to 21 existing holdings. Its largest new stake was Septerna Inc: 2,202,514 shares worth $50.4M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Scholar Rock, an estimated $65.4M trimmed.

  • Siren LLC's largest Q4 2024 buy was Septerna Inc: 2,202,514 shares worth $50.4M.
  • Siren LLC added most to NewAmsterdam Pharma in Q4 2024, an estimated $25M increase.
  • Siren LLC's biggest Q4 2024 reduction was Scholar Rock, cutting an estimated $65.4M.
  • Siren LLC fully exited Longboard Pharmaceuticals, Inc. Common Stock in Q4 2024, selling an estimated $30.1M.
  • Siren LLC's ten largest holdings make up 49% of its $2.26B portfolio in Q4 2024.
  • Siren LLC opened 22 new positions and closed 16 in Q4 2024.
  • Siren LLC's portfolio value rose 13% quarter-over-quarter to $2.26B.

Based on Siren LLC's 13F filing for Q4 2024, filed 14 Feb 2025.